1. Cell Biology

An amphipathic helix in Brl1 is required for nuclear pore complex biogenesis in S. cerevisiae

  1. Annemarie Kralt
  2. Matthias Wojtynek
  3. Jonas S Fischer
  4. Arantxa Agote-Aran
  5. Roberta Mancini
  6. Elisa Dultz
  7. Elad Noor
  8. Federico Uliana
  9. Marianna Tatarek-Nossol
  10. Wolfram Antonin
  11. Evgeny Onischenko
  12. Ohad Medalia
  13. Karsten Weis  Is a corresponding author
  1. Institute of Biochemistry, Department of Biology, ETH Zurich, Switzerland
  2. Department of Biochemistry, University of Zurich, Switzerland
  3. Department of Plant and Environmental Sciences, Weizmann Institute of Science, Israel
  4. Institute of Biochemistry and Molecular Cell Biology, Medical School, RWTH Aachen University, Germany
  5. Department of Biological Sciences, University of Bergen, Norway
https://doi.org/10.7554/eLife.78385
Share this article
Cite this article
  1. Annemarie Kralt
  2. Matthias Wojtynek
  3. Jonas S Fischer
  4. Arantxa Agote-Aran
  5. Roberta Mancini
  6. Elisa Dultz
  7. Elad Noor
  8. Federico Uliana
  9. Marianna Tatarek-Nossol
  10. Wolfram Antonin
  11. Evgeny Onischenko
  12. Ohad Medalia
  13. Karsten Weis
(2022)
An amphipathic helix in Brl1 is required for nuclear pore complex biogenesis in S. cerevisiae
eLife 11:e78385.
https://doi.org/10.7554/eLife.78385
  2. Download BibTeX
  3. Download .RIS
11 figures, 3 tables and 5 additional files

Figures

Figure 1 with 1 supplement
Download asset Open asset
Brl1 preferentially binds young nuclear pore complexes (NPCs).

(A) Scheme of the NPC architecture. The colors indicate the assembly order as found in Onischenko et al., 2020. Nucleoporins (NUPs) that were reproducibly identified in Brl1 affinity purifications are shown in bold. (B) Schematic illustrating the transient binding of an NPC assembly factor during NPC assembly. (C) Enrichment of Brl1 in affinity pulldowns from Onischenko et al., 2020 using baits from the different assembly tiers. Early and intermediate tiers contain four different baits each; the late tier is represented by Mlp1 with three biological replicates for each bait. (D) Schematic representation of the recombination-induced tag exchange (RITE) strategy to visualize Brl1-mCherry co-localization with old or new NPCs marked by Nup170-yEGFP and the expected NE fluorescence intensity profiles. (E) Representative co-localization images of Brl1-mCherry with old or new Nup170-yEGFP marked NPCs using the RITE strategy described in (D). Cells were imaged ~30 min or ~5 hr after recombination induction, respectively. Fluorescence intensity profiles along the NE are displayed for cells denoted with an asterisk. (F) Pearson’s correlation between Nup170-yEGFP and Brl1-mCherry fluorescence intensity profiles along the NE in (E). Individual points reflect the average of a biological replicate with a minimum of 28 analyzed NE contours per condition. Two-tailed Student’s t-test (n = 5, p-value=0.00015).

Figure 1—source data 1

Label-free Brl1 intensities with 10 nucleoporin (NUP) baits from Onischenko et al., 2020; related to Figure 1C.

https://cdn.elifesciences.org/articles/78385/elife-78385-fig1-data1-v1.xlsx
Figure 1—source data 2

Pearson’s correlation coefficients for Brl1-mCherry and new or old Nup170-yeGFP.

https://cdn.elifesciences.org/articles/78385/elife-78385-fig1-data2-v1.xlsx
Figure 1—figure supplement 1
Download asset Open asset
Proteomic characterization of Brl1 nuclear pore complex (NPC) interactions.

(A) All 1500 proteins co-purified in affinity pulldowns with 10 different nucleoporin (NUP) baits (Onischenko et al., 2020) were ranked by their fold enrichment difference between early and late tier baits. Mean ± SEM of three biological replicates. (B) Log10 abundance of NUPs belonging to the different assembly tiers in Brl1 affinity pulldowns (APs). Values for three biological replicates. (C) Reproducibility of the fractional labeling in KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies) assays with Brl1. Individual points correspond to the fractional labeling of a protein. (D) Heatmap showing the fractional labeling of NUPs in KARMA assays with Brl1 bait.

Figure 1—figure supplement 1—source data 1

Label-free nucleoporin/nuclear transport receptor (NUP/NTR) intensities with Brl1 bait (related to Figure 1—figure supplement 1B).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig1-figsupp1-data1-v1.xlsx
Figure 2
Download asset Open asset
Mapping Brl1 association with nuclear pore complex (NPC) assembly intermediates using KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies).

(A) Principles of KARMA: newly synthesized proteins are pulse-labeled followed by the affinity purification of the nucleoporin (NUP) complexes through a tagged NPC-binding protein. The extent of metabolic labeling is then quantified by mass spectrometry and corresponds to the average protein age in the affinity-purified fraction. An assembly factor selectively binds young NPCs, thus leading to high metabolic labeling rates for NUPs present in the intermediates (1). This is not the case for proteins that join after the assembly factor completely or partially dissociates or when the process is probed with an NUP bait (2). (B) Comparison of the labeling rates for NUPs and nuclear transport receptors (NTRs) in KARMA assays with Brl1 bait (left, this study) and with 10 different NUP baits (right, Onischenko et al., 2020). Median of three biological replicates. (C) Inaccessible pool of NUPs in KARMA assays with Brl1 compared to NUP baits (Onischenko et al., 2020), evaluated using a three-state kinetic state model (KSM) (Onischenko et al., 2020). (D) Barplot depicting the extent of metabolic labeling for different NUPs in KARMA assays with Brl1 bait after 90 min. The dotted line indicates the median NTR labeling. Median ± SD of three biological replicates. (E) Fractional labeling values from 2D averaged for NPC subcomplexes and offset by NTR labeling projected onto the NPC scheme.

Figure 2—source data 1

Fractional labeling of nucleoporins/nuclear transport receptors (NUPs/NTRs) in Brl1 KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies) assays (related to Figure 2 and Figure 1—figure supplement 1).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig2-data1-v1.xlsx
Figure 2—source data 2

Inaccessible pools as estimated by the three-step kinetic state model (KSM) (Onischenko et al., 2020) for Brl1 and NUP baits (related to Figure 2C).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig2-data2-v1.xlsx
Figure 3 with 5 supplements
Download asset Open asset
Brl1 degradation interferes with nuclear pore complex (NPC) assembly.

(A) Tomographic slices of focused ion beam (FIB)-milled, 4–4.5 hr auxin-treated Brl1-AID cells showing the structures quantified in (B). Image frames colored according to the color code used in (B). Scale bar 100 nm; black arrows: herniations; white arrow: NPC; N: nucleus; C: cytoplasm; slice thickness i and iii: 1.4 nm; ii and iv: 2.8 nm. Panels i and ii were cropped from tomographic slices from the tomograms in Figure 3—videos 1 and 2. (B) Quantification of 27 tomograms (8.5 µm2 NE) and 51 (16.7 µm2 NE) for -OsTIR1 and +OsTIR1, respectively. (C) Example fluorescent micrographs of yEGFP-tagged nucleoporins (NUPs) in 4–4.5 hr auxin-treated Brl1-AID ± OsTIR1 cells. (D) Normalized fluorescence intensity signal in the nuclear envelope in ±OsTIR1 Brl1-AID cells treated with 500 µM auxin for 4–4.5 hr. Mean ± SEM of a minimum of two biological replicates. (E) Recombination-induced tag exchange (RITE) method is combined with a CRE-EBD recombinase to conditionally switch fluorescence tags upon β-estradiol addition. (F) NUP RITE fusion protein localization in the Brl1-AID background 3 hr after treating cells with auxin (+auxin) or ethanol (-auxin). Recombination was induced 30 min prior to auxin addition.

Figure 3—figure supplement 1
Download asset Open asset
Characterization and subtomogram analysis of Brl1 depletion.

(A) Auxin-inducible degradation of Brl1 (Nishimura et al., 2009). Interaction between degron-tagged Brl1 and the E3 ubiquitin ligase SCF is mediated by the auxin-binding receptor OsTir1. (B) Depletion of Brl1-AID monitored by Western blotting. Brl1-V5-IAA7 was detected with an anti-V5 antibody, anti-hexokinase served as loading control. Mean ± SEM of three biological replicates. (C) Growth rate of Brl1-AID±OsTir1 cells incubated with 500 µM auxin or an equivalent amount of ethanol (-auxin). (D) Subtomograms and subtomogram averages of nuclear pore complexes (NPCs) and NPC-like structures in Brl1-depleted conditions; (i) inner nuclear membrane (INM) evaginations, (ii) nuclear envelope (NE) herniations, and (iii) mature NPCs. Diameter and number of particles are indicated. Cytoplasm is pointing up in all images. Box size of single herniations/NPCs is 270 nm. Red boxes indicate NPC-like densities at the neck of herniations. (E) Fourier shell correlation (FSC) curves for the subtomogram averages in D and Figure 7. FSC0.5 indicated as dotted line. (F) Tomographic slices of focused ion beam (FIB)-milled 4–4.5 hr auxin-treated Brl1-AID cells; slices through herniations show a luminal ring around the herniation, highlighted in yellow, NPC membrane in red; the rotation axis is indicated by a dashed line; scale bars: 100 nm; slice thickness: 1.4 nm.

Figure 3—figure supplement 1—source data 1

Uncropped Western blots (related to Figure 3—figure supplement 1B, Figure 5E and F).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig3-figsupp1-data1-v1.pdf
Figure 3—video 1
Download asset
Sequential sections of a cryo-tomogram from Brl1-depleted cells.

The tomogram is 6× binned; pixel size: 2.1 nm; scale bar: 100 nm.

Figure 3—video 2
Download asset
Sequential sections of a cryo-tomogram from Brl1- depleted cells.

The tomogram is 6x binned; pixelsize: 2.1nm; scalebar: 100nm.

Figure 3—video 3
Download asset
Sequential sections of a cryo-tomogram from non-depleted Brl1 control cells.

The tomogram is 6× binned; pixel size: 2.1 nm; scale bar: 100 nm.

Figure 3—video 4
Download asset
Sequential sections of a cryo-tomogram from non-depleted Brl1 control cells.

The tomogram is 6x binned; pixelsize: 2.1nm; scalebar: 100nm.

Figure 4 with 1 supplement
Download asset Open asset
Proteomic characterization of nuclear pore complex (NPC) assembly intermediates induced by Brl1 depletion.

(A) Depiction of the metabolic labeling assays to examine NPC assembly effects that occur upon Brl1 degradation. Newly synthesized proteins are pulse-labeled simultaneously with the auxin-induced depletion of Brl1. Mature NPCs and assembly intermediates are purified via affinity-tagged Nup170. Newly made nucleoporins (NUPs) that depend on Brl1 for their incorporation cannot be purified with Nup170, thus diminishing the extent of their metabolic labeling in Nup170 affinity pulldown (AP) after Brl1 depletion. (B) Fractional labeling of bulk proteins compared to NUPs in KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies) assays with affinity-tagged Nup170 in Brl1-AID cells treated with auxin (+auxin) or ethanol (-auxin) for 4 hr. Data points correspond to the median values in three biological replicates. Two-tailed Student’s t-test (p-value: n.s. >0.05 and ****<0.0001). (C) Fractional labeling ratio of NUPs (bars) and bulk proteins (dotted line) in Nup170 APs from Brl1-AID cells treated with auxin (+auxin) or ethanol (-auxin). Mean ± SEM of three biological replicates and three time points (4, 4.5, and 5 hr post treatment, n = 9). Mlp1 and Mlp2 are missing in one replicate of the 4.5 time point (n = 8). (D) Left: fractional labeling ratios from (C) averaged per subcomplex and projected onto the NPC schematic. Right: nuclear envelope fluorescence intensity signal ratio from Figure 3D averaged for NPC subcomplexes and projected onto the NPC schematic.

Figure 4—source data 1

Fractional labeling in Brl1-AID Nup170 affinity pulldowns (APs) with and without auxin treatment (related to Figure 4).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig4-data1-v1.xlsx
Figure 4—figure supplement 1
Download asset Open asset
Exchange rates of nuclear pore complex (NPC) assembly intermediates in Brl1-depleted cells.

(A) Correlation between normalized nucleoporin (NUP) fractional labeling observed in Brl1 KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies) assays with the normalized fractional labeling ratios in Nup170 affinity pulldown (AP) from Brl1-AID cells with auxin or ethanol treatment. (B) Lysate intermixing assay to test the extent of dynamic exchange during the AP procedure. Brl1-AID cells are either treated with auxin or ethanol for 5 hr, then equal fractions of cell culture expressing tagged Nup170, grown in light lysine medium and wildtype culture grown in metabolic labeled medium were subjected to the AP procedure. (C) Intermixing of NUPs (black) and nuclear transport receptors (NTRs) (brown) along with other co-purified proteins (gray) with auxin (+auxin) or ethanol (-auxin) treatment. Values are normalized to the mean intermixing of all co-purified non-NUP proteins in a sample (=100%). Median of three biological replicates. (D) Intermixing extent for NUPs and NTRs in Nup170 APs in Brl1-AID cells treated with auxin (white) or ethanol (black). Normalized as in Figure 3C. Median ± SD of three biological replicates.

Figure 4—figure supplement 1—source data 1

Fractional labeling in the lysis intermixing tests for Nup170 bait (related to Figure 4—figure supplement 1).

https://cdn.elifesciences.org/articles/78385/elife-78385-fig4-figsupp1-data1-v1.xlsx
Figure 5 with 2 supplements
Download asset Open asset
A conserved luminal amphipathic helix binds to membranes and is essential for Brl1 function.

(A) AlphaFold prediction for Brl1 (Jumper et al., 2021). Unstructured termini are not shown; blue: N-terminus; red: C-terminus. Transmembrane domain highlighted by the lipid bilayer. (B) Predicted amphipathic helix in ribbon and surface representation, colored based on hydrophobicity. (C) Upper panel: domain architecture of Brl1: extraluminal N- and C-terminus in brown, transmembrane domains in dark gray, amphipathic helix in red; left panel: helical wheel representation of the amphipathic helix of Brl1 and the hydrophobic moment determined with HeliQuest (Gautier et al., 2008). Point mutants are indicated by stars. Right panel: conservation and secondary structure prediction of the amphipathic helix in different fungi (full alignment in Figure 5—figure supplement 2A and B). Hydrophobic: blue; negative: magenta; polar: green; glycine: orange; proline: yellow; unconserved: white. Jnetpred4 secondary structure prediction (Drozdetskiy et al., 2015): helices are marked as red tubes. Sc: Saccharomyces cerevisiae; Sp: Schizosaccharomyces pombe; Pc: Pneumocystis carinii; An: Aspergillus nidulans; Tp: Tetrapisispora phaffii; Ka: Kazachstania africana; Cl: Clavispora lusitaniae; Dh: Debaryomyces hansenii. (D) Vertically oriented tetrad offspring of heterozygous Brl1 mutants carrying one allele lacking the amphipathic helix (brl1Δah) or a single-point mutation in the hydrophobic side of the helix (brl1(I395D)). (E) Membrane flotation assay with purified MBP-ahBrl1(377-406)-yEGFP fusion proteins and liposomes made of E. coli polar lipids extract. Control: MBP-yeGFP. Mean of three biological replicates, individual data points are indicated. (F) Membrane flotation assay with purified MBP-ahBrl1(377-406)-yEGFP fusion using liposomes of different sizes. Control: MBP-yeGFP. Mean of three or six biological replicates for MBP-ahBrl1(377-406)-yEGFP, individual data points are indicated.

Figure 5—figure supplement 1
Download asset Open asset
AlphaFold structure prediction for Brl1.

(A) Predicted structure for full-length Brl1 using AlphaFold2, colored based on the predicted local distance difference test score (pLDDT). (B) pLDDT score for Brl1. High-confidence region shown in (E-G) and Figure 5 indicated by the red area. (C) Predicted aligned error for Brl1, dark green area indicates high inter-domain accuracy. High-accuracy region shown in (E-G) and Figure 5 is highlighted by the black frame. (D) Predicted structure for Brl1, colored in rainbow (red: C-terminus; blue: N-terminus); inset shows the position of the four cysteines in the luminal domain of Brl1. (E) Predicted structure for high-confidence region Brl1(289-434) in rainbow coloring (red: C-terminus; blue: N-terminus). (F, G) Surface representation of Brl1(289-434), colored by hydrophobicity (Kyte–Doolittle scale) (F) and charge (G).

Figure 5—figure supplement 2
Download asset Open asset
Conservation and structure prediction of Brl1 homologues in different fungi.

(A) Sequence alignment of full-length Brl1 homologues, black box indicates the zoom-in in panel. (B) Hydrophobic: blue, negative: magenta, red: positive polar: green, glycine: orange, proline: yellow, unconserved: white. Jnetpred4 secondary structure prediction (Drozdetskiy et al., 2015): helices are marked as red tubes. Sc: Saccharomyces cerevisiae; Sp: Schizosaccharomyces pombe; Pc: Pneumocystis carinii; An: Aspergillus nidulans; Tp: Tetrapisispora phaffii; Ka: Kazachstania africana; Cl: Clavispora lusitaniae; Dh: Debaryomyces hansenii. (C) AlphaFold structure prediction for Brl1 homologues. The mostly unstructured N- and C-termini were removed for clarity. Blue: helix 1; red: amphipathic helix; green: helix 2 (regions also indicated in panel B).

Figure 6 with 1 supplement
Download asset Open asset
Overexpression of Brl1(I395D) with an impaired amphipathic helix interferes with nuclear pore complex (NPC) assembly.

(A) Spotting assay of wildtype cells expressing Brl1, Brl1Δah, or Brl1(I395D) from the GAL1 promoter in glucose or galactose-containing medium. (B) Localization of yEGFP-tagged Brl1, Brl1Δah, or Brl1(I395D) from the GAL1 promoter in SD 2% galactose. Brightness contrast settings of nuclei in insets are adjusted differently. (C) Fluorescence recovery after photobleaching of Sec61-yEGFP, Brl1-mCherry and Brl1(I395D)-mCherry. Left panels: representative images of recovery; right: corresponding averaged recovery curves (n > 4). One representative experiment of three biological replicates is shown. Images are shown in pseudocolor. (D) Co-localization of mCherry-tagged Brl1 or Brl1(I395D) and yEGFP-tagged NUPs: mCherry channel is scaled differently between images. Maximum intensity plots of nucleoporins (NUPs) (green lines) relative to maximum Brl1(I395D)-mCherry signal in nuclear envelope (NE) foci (red line) from cytoplasm (bottom) to nucleoplasm (top). The arrows in the inset and the x-axis indicate the direction of measurement. Average and standard deviation of more than 38 line plots with n > 31 values averaged for each point. A representative image used for the analysis is shown for each condition in the inset.

Figure 6—source code 1

Fluorescence recovery after photobleaching (FRAP) analysis.

https://cdn.elifesciences.org/articles/78385/elife-78385-fig6-code1-v1.zip
Figure 6—source data 1

Line plots.

https://cdn.elifesciences.org/articles/78385/elife-78385-fig6-data1-v1.xlsx
Figure 6—figure supplement 1
Download asset Open asset
Luminal amphipathic helix (AH) of Brl1 is involved in nuclear pore complex (NPC) biogenesis.

(A) Spotting assay of fivefold serial dilutions of nup116ΔGLFG PMET3-NUP188 cells expressing various ahBrl1 domain mutants from the GAL1 promoter. (B) Co-localization of mCherry-tagged Brl1 or Brl1(I395D) expressed from a galactose-inducible promoter with endogenously tagged Brl1-yEGFP. Lower panel: maximum intensity plots of Brl1 (green line) relative to maximum Brl1(I395D)-mCherry signal in nuclear envelope (NE) foci (red line) from nucleoplasm (left) to cytoplasm (right). Average and standard deviation for 55 line plots, every point is an average of n > 30 values. A representative image used for analysis is shown in the inset. The arrows in the inset and the x-axis indicate the direction of measurement. (C) Brl1(I395D)-mCherry under the control of a galactose promoter was overexpressed by switching cells to a medium containing 2% galactose simultaneously with the auxin-induced degradation of endogenous Brl1 (+auxin) or the treatment with ethanol (-auxin). Cells were imaged 6 hr after induction. Lower panel: quantification of the fraction of cells with at least one NE focus of Brl1(I395D) in cells overexpressing Brl1(I395D)-mCherry. Three biological replicates (points) with a minimum of 637 cells per replicate and their mean (bar) are shown. Two-tailed Student’s t-test (n = 3, p-value = n.s.).

Figure 7 with 4 supplements
Download asset Open asset
Brl1(I395D) overexpression leads to the formation of multilayered nuclear envelope (NE) herniations.

(A) Tomographic slices of the nuclear pore complex (NPC)-like structures quantified in (B), observed in focused ion beam (FIB)-milled cells overexpressing Brl1(I395D), scale bar: 100 nm. N: nucleus, C: cytoplasm, slice thickness: 2.1 nm, arrows indicate NPC-like structures. Image frames colored according to the color code used in (B). Panels iv and vi are tomographic slices from the tomogram in Figure 7—video 1. (B) Quantification of observed structures in Brl1(I395D) cells and control condition; 17 (5.1 µm2 NE) and 50 (9.8 µm2 NE) tomograms were quantified for cells overexpressing Brl1 or Brl1(I395D), respectively. (C) Single subtomograms and the subtomogram average of 47 herniations in Brl1(I395D) overexpressing cells; box size of subtomograms is 270 nm; cytoplasm is at the top in each image. Red boxes indicate NPC-like densities at the neck of herniations.

Figure 7—video 1
Download asset
Sequential sections of a cryo-tomogram from Brl1(I395D)-overexpressing cells.

The tomogram is 6× binned; pixel size: 2.1 nm; scale bar: 100 nm.

Figure 7—video 2
Download asset
Sequential sections of a cryo-tomogram from Brl1(I395D)-overexpressing cells.

The tomogram is 6x binned; pixelsize: 2.1nm; scalebar: 100nm.

Figure 7—video 3
Download asset
Sequential sections of a cryo-tomogram from Brl1-overexpressing cells.

The tomogram is 6× binned; pixel size: 2.1 nm; scale bar: 100 nm.

Figure 7—video 4
Download asset
Sequential sections of a cryo-tomogram from Brl1-overexpressing cells.

The tomogram is 6x binned; pixelsize: 2.1nm; scalebar: 100nm.

Figure 8
Download asset Open asset
The role of Brl1 during nuclear pore complex (NPC) assembly.

(A) Brl1 (red) enriches on the inside of NPC maturation intermediates and promotes inner nuclear membrane–outer nuclear membrane (INM-ONM) fusion through the membrane-binding amphipathic helix (AH) motif and likely in cooperation with Brr6 (yellow). (B) If Brl1 cannot reach the critical concentration required to promote membrane fusion, unresolved nuclear envelope (NE) herniations, filled with electron-dense material, appear. (C) Overexpressed Brl1(I395D) with a perturbed AH (blue) concentrates at the NPC assembly site. It remodels the NE membranes and leads to expanded multilayered herniations but ultimately fails to induce membrane fusion. (D) Brl1 at the INM can only physically interact with Brr6 or Brl1 at the ONM when the NE leaflets approach as it is the case at NPC assembly sites. Dimensions based on our cryo-electron tomography (cryo-ET) data (Figure 3—figure supplement 1D), structure prediction (Figure 5—figure supplement 1), and measurements of the NE (Appendix 1—figure 2B).

Appendix 1—figure 1
Download asset Open asset
Control of protein labeling in KARMA (Kinetic Analysis of Incorporation Rates in Macromolecular Assemblies) assays.

(A) Fractional labeling of nucleoporins (NUPs) and nuclear transport receptors (NTRs) in KARMA assays with Brl1 bait and the respective source lysate, 90 min after labeling onset. Median ± SD of three biological replicates. (B) Experiment to test the intermixing dynamics. Equal fractions of an unlabeled Brl1 affinity-tagged strain and a wildtype culture grown in metabolically labeled medium were subjected to the affinity purification procedure. (C) Percentage of intermixing for NUPs and NTRs normalized to the mean of all co-purified proteins with Brl1 bait. Median ± SD of three biological replicates. (D) Correlation of NUPs between fractional labeling in the intermixing experiment and in KARMA assay with Brl1 bait. Coloring according to the assembly tier. Median of three biological replicates each. (E) During complex assembly, proteins can dynamically exchange within the bait-bound fraction (green arrows) or between the bait-bound and unbound fractions (red arrows). The metabolic labeling in KARMA assays is only sensitive to dynamic exchange between bait-bound fractions and unbound fractions, whereas in the lysate intermixing assays both forms of exchange contribute to the observed labeling.

Appendix 1—figure 1—source data 1

Fractional labeling in the source lysate (parallel reaction monitoring [PRM] assay, related to Appendix 1—figure 1A).

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig1-data1-v1.xlsx
Appendix 1—figure 1—source data 2

Fractional labeling in the lysis intermixing tests with Brl1 bait (related to Appendix 1—figure 1B–D).

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig1-data2-v1.xlsx
Appendix 1—figure 2
Download asset Open asset
Potential maturation processes of onion-like herniations.

(A) Tomographic slice of an onion-like herniation and an example line plot with fitted Gaussians measured at the indicated red line. Brackets indicate how the distances were classified for the plot in B. (B) Violin plot with individual points of membrane–membrane distances. Mann–Whitney test, ****p-value<0.0001; ***p-value=0.0001. (C) Mode 1 for maturation of onion-like herniations. Top panel: tomographic slices of several stages of herniations in Brl1(I395D) overexpressing cells (nucleus always in the bottom); middle panel: membrane segmentation of the herniations of the upper panel. Inner nuclear membrane (INM): blue; outer nuclear membrane (ONM): red; ONM in the center of the very right panel was classified as ONM based on the presence of ribosomes and wider membrane spacing. Lower panel: schematic of how the onion-like herniations mature. (D) Same as (C) but for mode 2 of the maturation process of onion-like herniations. Scale bar: 100 nm. Slice thickness: 1.4 nm.

Appendix 1—figure 2—source data 1

Distance measurements.

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig2-data1-v1.xlsx
Author response image 1
Download asset Open asset

Tables

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Chemical compound, drugIP6Sigma-AldrichP5681AID experiments
Chemical compound, drugAuxinSigma-AldrichI2886AID experiments
Chemical compound, drugβ-EstradiolSigma-AldrichE8875RITE experiments
Chemical compound, drugHygromycin BRoche10843555001RITE experiments
Chemical compound, drugConcanavalin A (ConA)Sigma-AldrichC2010Fluorescence microscopy
Chemical compound, drugIPTGAppliChemA10080025Protein expression
Chemical compound, drugProtease inhibitor cocktailSigma-AldrichP8215MS assays
Chemical compound, drugPurified IgG protein from rabbit serumSigma-AldrichI5006MS assays
Chemical compound, drugCoomassie Brilliant Blue R-250Bio-Rad161-0400MS assays
Chemical compound, drugSequencing grade porcine trypsinPromegaV5113MS assays
Chemical compound, drugL-Lysine:2HCL (13C6, 99%; 15N2, 99%)Cambridge Isotope LaboratoriesCNLM-291-H-0.25MS assays
Chemical compound, drugIodoacetamideSigma-AldrichI1149MS assays
Chemical compound, drugAmmonium bicarbonateSigma-Aldrich09832MS assays
Chemical compound, drugFormic acid 99–100%VWR Chemicals20318.297MS assays
Chemical compound, drugiRT KitBiognosisKi-3002-1MS assays
Chemical compound, drugBioPureSPN MINI Columns Silica C18The Nest Group, IncHUM S18VMS assays
Chemical compound, drugBioPureSPN MACRO Columns Silica C18The Nest Group, IncHMM S18VMS assays
Peptide, recombinant proteinDNase IRoche10104159001Protein purification
Chemical compound, drugcOmplete Protease Inhibitor CocktailRoche05053489001Protein purification
OtherNi-NTA AgaroseQIAGEN30210Protein purification
Antibodyα-V5 (mouse monoclonal)InvitrogenR960-25Western blotting, 1:2000
Antibodyα-Hexokinase (rabbit monoclonal)US BiologicalsH2035-01Western blotting, 1:3000
Antibodyα-Mouse IgG Alexa Fluor 680 (goat polyclonal)Thermo Fisher ScientificA-21057Western blotting,
1:10,000
Antibodyα-Rabbit IgG IRDye800CW (goat polyclonal)Li-COR Biosciences926-32211Western blotting,
1:10,000
Antibodyα-EGFP (mouse monoclonal)Roche11814460001Liposome experiments, 1:2000
Antibodyα-Mouse IgG peroxidase conjugate (goat polyclonal)Calbiochem401215Liposome experiments, 1:5000
OtherZymolyase
100T		ICN320932Tetrad dissection
OtherE. coli polar lipidsAvanti Polar Lipids100600CLiposome experiments
Other18:1 Liss Rhodamine PEAvanti Polar Lipids810150CLiposome experiments
Software, algorithmNuRimRajoo et al., 2018; Vallotton et al., 2019Data analysis
Software, algorithmImageJ/FijiSchindelin et al., 2012Data acquisition
Software, algorithmNIS ElementsNikonData acquisition
Software, algorithmMATLABMathWorksData analysis
Software, algorithmIMODhttps://bio3d.colorado.edu/imod/Data analysis
Software, algorithmSerialEMMastronarde, 2003Data acquisition
Software, algorithmUCSF ChimeraPettersen et al., 2004Data visualization
Software, algorithmSBGridMorin et al., 2013Data processing
Software, algorithmTOM toolboxNickell et al., 2005; Förster et al., 2005, https://www.biochem.mpg.de/6348566/tom_eData processing
Software, algorithmAlphaFold2.1.1Jumper et al., 2021Data analysis
Software, algorithmAlphaFold visualizationhttps://colab.research.google.com/drive/1CizC7zmYvFkav5qfBbWxhgUHrOxwym2wData analysis
Software, algorithmCOBALThttps://www.ncbi.nlm.nih.gov/tools/cobalt/re_cobalt.cgiSequence alignment
Software, algorithmJalviewWaterhouse et al., 2009Sequence alignment
Software, algorithmExcelMicrosoftData analysis
Software, algorithmR v. 4.1.2R ProjectData analysis
Software, algorithmPrism 7
Prism 9		GraphPadVisualization
Software, algorithmInkscape 1.1https://inkscape.org/Visualization
Software, algorithmIllustrator v. 26.0.3AdobeVisualization
Table 1
Plasmids used in this study.
IDDescriptionDetailsSource
pKW4689pRS306-pGAL1-yEGFPIntegration in ura3 locus, expression of yEGFPThis study
pKW4558pRS306-pGAL1-ahBrl1-yEGFPIntegration in ura3 locus, expression of ahBrl1-yEGFPThis study
pKW4578pRS306-pGAL1-MRATSKIntegration in ura3 locus, overexpression of small peptide MRATSKThis study
pKW4568pRS306-pGAL1-BRL1Integration in ura3 locus, overexpression of Brl1This study
pKW4649pRS306-pGAL1-BRL1-yEGFPIntegration in ura3 locus, overexpression of Brl1-yEGFPThis study
pKW4651pRS306-pGAL1-BRL1Δah-yEGFPIntegration in ura3 locus, overexpression of BRL1Δah-yEGFPThis study
pKW4712pRS306-pGAL1-BRL1(I395D)-yEGFPIntegration in ura3 locus, overexpression of Brl1(I395D)-yEGFPThis study
pKW589pRS305Integration in leu2 locusSikorski and Hieter, 1989
pKW4915pRS305-pGAL1-BRL1-mCherryIntegration in leu2 locus, overexpression of Brl1-mCherryThis study
pKW4919pRS305-pGAL1-BRL1(I395D)-mCherryIntegration in leu2 locus, overexpression of Brl1(I395D)-mCherryThis study
pKW1358Ylplac204-pTPI1-dsRED-HDELIntegration in trp1 locus, ER markerBevis and Glick, 2002
pKW1964pFA6A-link-yEGFP-CaURA3PCR template for endogenous tagging with yEGFPSheff and Thorn, 2004
pKW3359pFA6a-NH605-3V5-IAA7-KanMX6PCR template for endogenous tagging with V5-IAA7Derrer et al., 2019
pKW2874pNH603-pGPD1-osTIR1-HIS3MXIntegration in his3 locus, OsTIR1 expressionDerrer et al., 2019
pKW2830pNH603-pGPD1-osTIR1-LEU2Integration in leu2 locus, OsTIR1 expressionChan et al., 2018
pKW354pRS4262µ–URA3 plasmidChristianson et al., 1992
pKW4468pRS426-BRL12µ–URA3 plasmid containing BRL1 locusThis study
pKW4659pSV272-6xHis-MBP-TEV-yEGFPBacterial expression of 6xHis-MBP-TEV-yEGFPThis study
pKW4660pSV272-6xHis-MBP-TEV-ahBrl1-yEGFPBacterial expression of 6xHis-MBP-TEV-ahBrl1-yEGFPThis study
pKW4683pSV272-6xHis-MBP-TEV-ahBrl1(F391D)-yEGFPBacterial expression of 6xHis-MBP-TEV-ahBrl1(F391D)-yEGFPThis study
pKW4684pSV272-6xHis-MBP-TEV-ahBrl1(I395D)-yEGFPBacterial expression of 6xHis-MBP-TEV-ahBrl1(I395D)-yEGFPThis study
pKW4612pRS306-pGAL1-BRL1(F391D)Integration in ura3 locus, overexpression of Brl1(F391D)This study
pKW4613pRS306-pGAL1-BRL1(I395D)Integration in ura3 locus, overexpression of Brl1(I395D)This study
pKW4614pRS306-pGAL1-BRL1(F398D)Integration in ura3 locus, overexpression of Brl1(F398D)This study
pKW4615pRS306-pGAL1-BRL1(L402D)Integration in ura3 locus, overexpression of Brl1(L402D)This study
pKW4616pRS306-pGAL1-BRL1(D393A)Integration in ura3 locus, overexpression of Brl1(D393A)This study
pKW4617pRS306-pGAL1-BRL1(D400A)Integration in ura3 locus, overexpression of Brl1(D400A)This study
pKW3061pRS303-GPD-CRE-EBD78Integration in his3 locus CRE-EBD78 expressionTerweij et al., 2013
pKW804pFA6-S-TEV-ZZ-KanMXPCR template for endogenous tagging with S-TEV-ZZOnischenko et al., 2020
pKW953pFA6-S-TEV-ZZ-URA3PCR template for endogenous tagging with S-TEV-ZZThis study
pKW4746pFa6a-loxP-HA-mCherry-HygMX-loxP-GFPPCR template for endogenous tagging with loxP-HA-mCherry-HygMX-loxP-GFPColombi et al., 2013
pKW2407pFA6a-mCherry-NATPCR template for endogenous tagging with mCherryOnischenko et al., 2020
pKW4945pFA6a-loxP-yEGFP_URA3-loxPPCR template for endogenous tagging with loxP-yEGFP_URA3-loxPThis study
pKW4946pFA6a-loxP-URA3-loxP_yEGFPPCR template for endogenous tagging with loxP-URA3-loxP_yEGFPThis study
Table 2
Yeast strains used in this study.
IDGenotypeSource
KWY165haploid, MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 [phi+]W303 haploid
KWY166diploid, leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 [phi+]W303 diploid
KWY1602MAT(alpha) his3-1 leu2-0 lys2-0 ura3-0BY4742
KWY9200KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1This study
KWY9204KWY165, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1This study
KWY9268KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP82::NUP82-yEGFP-URA3This study
KWY9269BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP82::NUP82-yEGFP-URA3This study
KWY9270KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP116::NUP116-yEGFP-URA3This study
KWY9271KWY165, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP116::NUP116-yEGFP-URA3This study
KWY9272KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP100::NUP100-yEGFP-URA3This study
KWY9273KWY165, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP100::NUP100-yEGFP-URA3This study
KWY9274KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP133::NUP133-yEGFP-URA3This study
KWY9275KWY165, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP133::NUP133-yEGFP-URA3This study
KWY9276KWY165, BRL1::BRL1-V5-IAA7-KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP170::NUP170-yEGFP-URA3This study
KWY9277KWY165, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP170::NUP170-yEGFP-URA3This study
KWY9908KWY165, BRL1::BRL1-V5-IAA7 KanMX trp1::ADH1-dsRED-HDEL-TRP1 NUP60::NUP60-yEGFP-URA3This study
KWY10108KWY165, BRL1::BRL1-V5-IAA7 KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP60::NUP60-yEGFP-URA3This study
KWY9909KWY165, BRL1::BRL1-V5-IAA7 KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP159::NUP159-yEGFP-URA3This study
KWY10109KWY165, BRL1::BRL1-V5-IAA7 KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP159::NUP159-yEGFP-URA3This study
KWY9911KWY165, BRL1::BRL1-V5-IAA7 KanMX trp1::pADH1-dsRED-HDEL-TRP1 MLP1::MLP1-yEGFP-URA3This study
KWY10110KWY165, BRL1::BRL1-V5-IAA7 KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 MLP1::MLP1-yEGFP-URA3This study
KWY9939KWY165, BRL1::BRL1-V5-IAA7 KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP85::NUP85-yEGFP-URA3This study
KWY10107KWY165, BRL1::BRL1-V5-IAA7 KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP85::NUP85-yEGFP-URA3This study
KWY10029KWY165, BRL1::BRL1-V5-IAA7 KanMX trp1::pADH1-dsRED-HDEL-TRP1 NUP192::NUP192-yEGFP-URA3This study
KWY10111KWY165, BRL1::BRL1-V5-IAA7 KanMX his3::pGPD1-OsTIR1 trp1::pADH1-dsRED-HDEL-TRP1 NUP192::NUP192-yEGFP-URA3This study
KWY5540KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188Onischenko et al., 2017
KWY8891KWY165, ura3::pGAL1-BRL1-yeGFP-CaURA3This study
KWY8893KWY165, ura3::pGAL1-BRL1Δah-yeGFP-CaURA3This study
KWY9070KWY165, ura3::pGAL1-BRL1(I395D)-yeGFP-CaURA3This study
KWY8894KWY165, ura3::pGAL1-MRATSK-CaURA3This study
KWY8895KWY165, ura3::pGAL1-BRL1-CaURA3This study
KWY8896KWY165, ura3::pGAL1-BRL1Δah-CaURA3This study
KWY8898KWY165, ura3::pGAL1-BRL1(I395D)-CaURA3This study
KWY10154KWY165, NUP82::NUP82-yeGFP-CaURA3 leu2::pRS305-LEU2This study
KWY10155KWY165, NUP82::NUP82-yeGFP-CaURA3 leu2::pGAL1-BRL1-mCherry-LEU2This study
KWY10159KWY165, NUP82::NUP82-yeGFP-CaURA3 leu2::pGAL1-BRL1(I395D)-mCherry-LEU2This study
KWY10161KWY165, NUP116::NUP116-yeGFP-CaURA3 leu2::pRS305-LEU2This study
KWY10162KWY165, NUP116::NUP116-yeGFP-CaURA3 leu2::pGAL1-BRL1-mCherry-LEU2This study
KWY10166KWY165, NUP116::NUP116-yeGFP-CaURA3 leu2::pGAL1-BRL1(I395D)-mCherry-LEU2This study
KWY10168KWY165, NUP133::NUP133-yeGFP-CaURA3 leu2::pRS305-LEU2This study
KWY10169KWY165, NUP133::NUP133-yeGFP-CaURA3 leu2::pGAL1-BRL1-mCherry-LEU2This study
KWY10173KWY165, NUP133::NUP133-yeGFP-CaURA3 leu2::pGAL1-BRL1(I395D)-mCherry-LEU2This study
KWY10175KWY165, NUP170::NUP170-yeGFP-CaURA3 leu2::pRS305-LEU2This study
KWY10176KWY165, NUP170::NUP170-yeGFP-CaURA3 leu2::pGAL1-BRL1-mCherry-LEU2This study
KWY10180KWY165, NUP170::NUP170-yeGFP-CaURA3 leu2::pGAL1-BRL1(I395D)-mCherry-LEU2This study
KWY10260KWY165, SEC61::SEC61-yEGFP-CaURA3 leu2-3::pRS305-LEU2This study
KWY10261KWY165, SEC61::SEC61-yEGFP-CaURA3 leu2-3::BRL1-mCherry-LEU2This study
KWY10262KWY165, SEC61::SEC61-yEGFP-CaURA3 leu2-3::BRL1(I395D)-mCherry-LEU2This study
KWY8876KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1Δah-URA3This study
KWY8874KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1-URA3This study
KWY8877KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-MRATSK-URA3This study
KWY8882KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(F391D)-URA3This study
KWY8883KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(I395D)-URA3This study
KWY8884KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(F398D)-URA3This study
KWY8885KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(L402D)-URA3This study
KWY8886KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(D393A)-URA3This study
KWY8887KWY165, nup116ΔGLFG NUP188::HIS3MX-pMet3-3xHA-Nup188 ura3::pGAL1-BRL1(D400A)-URA3This study
KWY9079KWY165, trp1::dsRed-HDEL-TRP1 ura3::pGAL1-ahBRL1-yEGFP-CaURA3This study
KWY9075KWY165, trp1::dsRed-HDEL-TRP1 ura3::pGAL1-yEGFP-CaURA3This study
KWY10418KWY165, Brl1-mCherry::Nat his3::CRE-EBD78 NUP170::NUP170-loxP-GFP_URA3-loxP_STOPThis study
KWY10419KWY165, Brl1-mCherry::Nat his3::CRE-EBD78 NUP170::NUP170-loxP-STOP_URA3-loxP_GFPThis study
KWY9964KWY1602, BRL1::BRL1-S-TEV-ZZ-KanMXThis study
KWY10453KWY1602, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 NUP170::NUP170-S-TEV-ZZ-URA3This study
KWY10241KWY1602, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1This study
KWY10697KWY1602, BRL1::BRL1-V5-IAA7-KanMX his3::pGPD1-OsTIR1 ura3::Nup82-yEGFP leu2-3::BRL1(I395D)-mCherry-LEU2This study
KWY10445KWY1602, BRL1::BRL1-V5-IAA7-KanMX leu2::pGPD1-OsTIR1 MLP1::MLP1-V5-loxP-mCherry_HygMX-loxP_GFP his3::CRE-EBD78This study
KWY10450KWY1602, BRL1::BRL1-V5-IAA7-KanMX leu2::pGPD1-OsTIR1 NUP82::NUP82-V5-loxP-mCherry_HygMX-loxP_GFP his3::CRE-EBD78This study
KWY10451KWY1602, BRL1::BRL1-V5-IAA7-KanMX leu2::pGPD1-OsTIR1 NUP188::NUP188-V5-loxP-mCherry_HygMX-loxP_GFP his3::CRE-EBD78This study
KWY10452KWY1602, BRL1::BRL1-V5-IAA7-KanMX leu2::pGPD1-OsTIR1 NUP133::NUP133-V5-loxP-mCherry_HygMX-loxP_GFP his3::CRE-EBD78This study
KWY9485KWY166, BRL1/brl1ΔahThis study
KWY9489KWY166, BRL1/brl1(I395D)This study

Additional files

MDAR checklist
https://cdn.elifesciences.org/articles/78385/elife-78385-mdarchecklist1-v1.pdf
Transparent reporting form
https://cdn.elifesciences.org/articles/78385/elife-78385-transrepform1-v1.pdf
Appendix 1—figure 1—source data 1

Fractional labeling in the source lysate (parallel reaction monitoring [PRM] assay, related to Appendix 1—figure 1A).

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig1-data1-v1.xlsx
Appendix 1—figure 1—source data 2

Fractional labeling in the lysis intermixing tests with Brl1 bait (related to Appendix 1—figure 1B–D).

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig1-data2-v1.xlsx
Appendix 1—figure 2—source data 1

Distance measurements.

https://cdn.elifesciences.org/articles/78385/elife-78385-app1-fig2-data1-v1.xlsx

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Annemarie Kralt
  2. Matthias Wojtynek
  3. Jonas S Fischer
  4. Arantxa Agote-Aran
  5. Roberta Mancini
  6. Elisa Dultz
  7. Elad Noor
  8. Federico Uliana
  9. Marianna Tatarek-Nossol
  10. Wolfram Antonin
  11. Evgeny Onischenko
  12. Ohad Medalia
  13. Karsten Weis
(2022)
An amphipathic helix in Brl1 is required for nuclear pore complex biogenesis in S. cerevisiae
eLife 11:e78385.
https://doi.org/10.7554/eLife.78385